Balyasny Asset Management
XBIT icon

Balyasny Asset Management’s XBiotech XBIT Stock Holding History

Balyasny Asset Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,865
Closed -$178K – 3182
2024
Q1 		$178K Buy
+21,865
New +$125K ﹤0.01% 2432
2020
Q2 		– Sell
-50,427
Closed -$536K – 1536
2020
Q1 		$536K Buy
+50,427
New +$821K 0.01% 892
2019
Q3 		– Sell
-213,100
Closed -$1.61M – 1650
2019
Q2 		$1.61M Sell
213,100
-58,847
-22% -$512K 0.01% 944
2019
Q1 		$3M Buy
+271,947
New +$2.2M 0.02% 715
2017
Q2 		– Sell
-65,000
Closed -$1.07M – 1790
2017
Q1 		$1.07M Buy
+65,000
New +$851K 0.01% 1074

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's XBIT Position: Q2 2024 in Review

Balyasny Asset Management sold out of XBiotech (XBIT) in Q2 2024, closing a stake of 21,865 shares — an estimated $178K sold.

Balyasny Asset Management first reported a position in XBIT in Q1 2017 and held it in 5 quarters. The position peaked at $3M in Q1 2019. 46 funds tracked by Wall St. Rank hold XBIT as of Q2 2024.

  • Balyasny Asset Management reported no remaining XBiotech position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 21,865 XBiotech shares in Q2 2024, an estimated $178K.
  • Balyasny Asset Management first reported a position in XBiotech in Q1 2017 and held it in 5 quarters.
  • Balyasny Asset Management's XBiotech position peaked at $3M in Q1 2019.
  • 46 funds tracked by Wall St. Rank held XBiotech as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.